Compare Endeavour Silver Corp (EXK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Novo Nordisk A/S — how do they compare? Endeavour Silver Corp trades at $7.44 (market cap $2.36B), while Novo Nordisk A/S trades at $51.45 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 94.2× Endeavour Silver Corp's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | NVO | |
|---|---|---|
Market Cap | $2.36B | $222.24B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $71.70 |
52-Week Low | $4.96 | $35.29 |
Enterprise Value | $2.36B | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $7.47, down 7.55% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 production of 3.4 million silver equivalent ounces and beat Q1 2026 earnings estimates with $0.21 EPS versus $0.10 expected. Despite negative net income margins and ROE, revenue growth is projected to improve from $468M in 2025 to $614M in 2026. Analyst sentiment remains positive with 78.57% buy ratings.
The outlook is mixed: operational momentum and silver price trends offer upside, but profitability challenges and high valuation ratios pose risks. Investors should weigh strong production growth against persistent negative earnings and cash flow concerns in a volatile commodity market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
